WebCognition Therapeutics, Inc. website 2403 Sidney Street Pittsburgh, PA 15203 Industry: Therapeutics Management Team: Chief Executive Officer: Lisa Ricciardi, M.B.A. Chief Medical Officer: Anthony O. Caggiano, M.D., Ph.D. Chief Financial Officer: James O’Brien, M.B.A. Founder and Chief Science Officer: Susan Catalano, Ph.D. Point of Contact: WebOct 16, 2024 · Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead ...
Board of Directors - Cognition Therapeutics, Inc.
WebNov 2, 2024 · From September 2016 to August 2024, Cognition Therapeutics ran a Phase 1/2 trial at four sites in Australia, enrolling 19 participants with mild to moderate Alzheimer's disease supported by a recent MRI. It compared a four-week course of 90, 280, or 560 mg of CT1812 to placebo, taken once daily, on safety and tolerability parameters. Web2 days ago · Cognition Therapeutics to Participate in the 2024 Cantor Fitzgerald Neurology & Psychiatry Conference. PURCHASE, N.Y., Sept. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and … chef justin hayes
Mild Cognitive Impairment Therapeutic Market 2024 - MarketWatch
WebFeb 4, 2024 · Cognition Therapeutics: ClinicalTrials.gov Identifier: NCT05225415 Other Study ID Numbers: COG1201 R01AG058660 ( U.S. NIH Grant/Contract ) First Posted: February 4, 2024 Key Record Dates: Last Update Posted: January 26, … WebMar 21, 2024 · Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease. Cognition Therapeutics … WebAug 2, 2024 · Pittsburgh, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of... fleetway travel from usa